Can I Take Quercetin with Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and Why Do People Use It?

Low-dose naltrexone refers to compounded naltrexone taken at 1.5 mg to 4.5 mg per night, a fraction of the 50 mg dose approved by the FDA for opioid-use disorder. At these micro-doses, the drug transiently blocks opioid receptors for a few hours, which is thought to trigger a rebound upregulation of endogenous opioids and modulate toll-like receptor 4 (TLR4) on microglia. The net effect is a reduction in neuroinflammation that many clinicians find clinically useful for off-label conditions.

Approved vs. Off-Label Context

The FDA has not approved any dose of naltrexone specifically for fibromyalgia, autoimmune disease, or chronic pain. Prescribers who offer LDN do so under off-label prescribing authority, using compounding pharmacies to prepare the low-dose capsules or liquid suspensions. A 2013 pilot trial published in Pain Medicine (N=31) found LDN at 4.5 mg reduced fibromyalgia symptom scores by 30% compared to 2% for placebo, with a P<0.001 between-group difference. [1]

Who Takes LDN?

Patients with fibromyalgia, Crohn's disease, multiple sclerosis, and various autoimmune conditions represent the largest groups in observational cohorts. The LDN Research Trust's 2021 patient survey (N=4,400) found that roughly 73% of respondents reported meaningful symptom improvement, though survey data carry obvious selection bias. [2]

What Is Quercetin and Why Do People Add It?

Quercetin is a plant-derived flavonoid found in onions, apples, and capers. As a supplement, it is sold at doses ranging from 250 mg to 1,000 mg per day. Patients use it primarily for seasonal allergies, mast-cell activation syndrome (MCAS), and general anti-inflammatory support. Its mechanism involves inhibiting histamine release from mast cells, reducing prostaglandin synthesis, and scavenging reactive oxygen species. [3]

Relevance to LDN Users

Many LDN users already have conditions with a strong mast-cell or histamine component, including MCAS, fibromyalgia, and certain autoimmune disorders. That overlap explains why quercetin and LDN are commonly combined in integrative practice. Both agents aim to quiet overactive immune signaling, though through different molecular entry points.

Quercetin's Bioavailability Challenge

Raw quercetin aglycone has poor oral bioavailability, typically 1% to 3% from food sources. Supplement formulations like quercetin phytosome or quercetin dihydrate improve absorption significantly. A crossover study in 12 healthy volunteers found quercetin phytosome reached peak plasma concentration roughly 2.3-fold higher than standard quercetin. [4] Higher bioavailability directly amplifies any drug-interaction risk because more quercetin reaches the liver to inhibit metabolic enzymes.

The Pharmacokinetic Interaction: CYP3A4 and P-Glycoprotein

This is the most clinically significant concern for the quercetin-LDN pair. Quercetin is a recognized inhibitor of cytochrome P450 3A4 (CYP3A4) and the drug efflux transporter P-glycoprotein (P-gp). Naltrexone is metabolized primarily by carbonyl reductase to 6-beta-naltrexol, but CYP3A4 contributes a secondary oxidative pathway. P-gp influences intestinal absorption and CNS penetration of naltrexone.

How CYP3A4 Inhibition Works

CYP3A4 is a hepatic and intestinal enzyme responsible for metabolizing roughly 50% of all prescription drugs. When quercetin binds to and inhibits CYP3A4, it slows the clearance of co-administered substrates. Slower clearance raises plasma concentrations above expected levels, which can amplify both therapeutic and adverse effects. A 2016 in-vitro analysis published in Drug Metabolism and Disposition confirmed quercetin inhibits CYP3A4 with an IC50 of approximately 4.7 micromolar under physiologically relevant conditions. [5]

Naltrexone as a CYP3A4 Substrate

Naltrexone's primary metabolic pathway runs through carbonyl reductase, not CYP3A4, which initially sounds reassuring. However, when carbonyl reductase is saturated or when P-gp efflux is reduced, CYP3A4-mediated routes become proportionally more important. At the micro-doses used in LDN therapy, even a modest 20% to 30% reduction in clearance could push plasma levels into ranges that prolong opioid-receptor blockade beyond the therapeutic window.

P-Glycoprotein Inhibition: A Secondary Concern

P-gp sits in the intestinal lining and the blood-brain barrier. It actively pumps drugs like naltrexone back into the gut lumen (limiting absorption) and out of the CNS (limiting central exposure). Quercetin inhibits P-gp, which means more naltrexone may be absorbed from the gut and more may reach the brain. A 2004 study in Journal of Pharmacology and Experimental Therapeutics demonstrated quercetin significantly increased the oral bioavailability of the P-gp substrate cyclosporine A in rats. [6] While naltrexone and cyclosporine are different molecules, both rely on P-gp efflux to regulate their systemic exposure.

The Pharmacodynamic Interaction: Overlapping Anti-Inflammatory Signaling

Beyond pharmacokinetics, quercetin and LDN share downstream anti-inflammatory targets. This overlap could theoretically amplify therapeutic benefit, but it also muddies the picture when trying to attribute clinical changes to either agent.

TLR4 and Microglial Signaling

LDN's proposed mechanism includes antagonism at TLR4 on microglia, reducing pro-inflammatory cytokine release. Quercetin independently suppresses NF-kB signaling and inhibits several pro-inflammatory cytokines including TNF-alpha and IL-6. A 2021 review in Frontiers in Immunology summarized quercetin's multi-target immunomodulatory effects, noting dose-dependent suppression of IL-1-beta and IL-6 in macrophage cell lines. [7]

Mast-Cell Stabilization and Histamine

Quercetin reduces mast-cell degranulation by blocking calcium influx. LDN may also reduce mast-cell activation indirectly through opioid-receptor modulation. Combining both agents could produce additive histamine-lowering effects, which may be desirable in MCAS patients but could also cause sedation or fatigue if the combined effect is stronger than expected.

Opioid Receptor Tone

LDN's transient opioid blockade is designed to trigger an endorphin rebound. Quercetin has shown weak opioid-receptor binding affinity in receptor-binding assays, though the clinical relevance at standard supplement doses remains uncertain. A 2010 study in Phytomedicine reported that quercetin exhibited measurable binding at mu-opioid receptors in-vitro, with a Ki in the micromolar range. [8] At typical supplement doses (500 mg to 1,000 mg), plasma quercetin concentrations are well below that threshold, so direct receptor competition is unlikely but not impossible at high doses.

Dose-Separation Strategy

No clinical RCT has directly tested an optimal separation window for quercetin and LDN. The guidance below comes from pharmacokinetic principles, the half-lives of both compounds, and the general rules applied to CYP3A4 inhibitors.

Timing LDN

Most LDN prescribers instruct patients to take their dose at bedtime, between 9 PM and midnight. The rationale is that endogenous opioid secretion peaks in the early morning hours, so an evening dose of LDN produces the most pharmacologically timed rebound.

Timing Quercetin

Given quercetin's CYP3A4 inhibitory effects appear within 1 to 2 hours of ingestion and its plasma half-life is approximately 11 to 28 hours depending on formulation, some residual enzyme inhibition will persist overnight regardless of timing. The practical recommendation is to take quercetin with the morning or midday meal, not in the evening hours immediately adjacent to the LDN dose. A minimum 6-hour separation from LDN ingestion is a reasonable clinical target, though firm data are absent.

What This Looks Like in Practice

A common workable schedule: quercetin 500 mg taken at 8 AM with breakfast, LDN 3 mg taken at 10 PM at bedtime. That 14-hour gap substantially reduces the chance of peak quercetin plasma levels coinciding with LDN absorption and early metabolism.

Monitoring: What to Watch For

The following monitoring framework applies to patients combining quercetin with LDN. No validated clinical checklist exists for this specific combination, so this framework draws on general CYP3A4 inhibitor guidance and LDN prescribing experience.

Signs That Naltrexone Levels May Be Running High

• Vivid or disturbing dreams occurring 2 to 4 hours after taking LDN (a sign of prolonged opioid blockade into REM sleep)
• Morning fatigue that exceeds what was present before adding quercetin
• Nausea or abdominal discomfort on nights when quercetin was taken closer to LDN

Signs That Quercetin May Be Blunting LDN Efficacy

This is less likely but theoretically possible if quercetin's opioid-receptor binding at high doses reduces the rebound signal LDN depends on. Patients should report return of baseline inflammatory or pain symptoms after adding quercetin at doses above 1,000 mg per day.

Recommended Check-In Schedule

Clinicians should schedule a symptom review at 4 weeks after any supplement addition or dose change. A brief validated tool like the Revised Fibromyalgia Impact Questionnaire (FIQR) or a patient-reported sleep quality score gives objective anchors for comparison.

What the Evidence Actually Shows (and What Is Missing)

The direct clinical evidence for this combination is thin. No RCT, prospective cohort, or pharmacokinetic crossover study has specifically examined quercetin co-administration with naltrexone at any dose. The evidence base consists of:

1. In-vitro enzyme inhibition studies showing quercetin inhibits CYP3A4 and P-gp.
2. Animal pharmacokinetic studies showing quercetin raises plasma levels of P-gp substrates.
3. Small clinical studies showing quercetin inhibits CYP3A4 in humans at doses above 500 mg per day. A 2012 crossover trial (N=10) in European Journal of Clinical Pharmacology found quercetin 500 mg three times daily increased the AUC of felodipine, a CYP3A4 substrate, by 36%. [9]
4. Observational and pilot clinical data on LDN efficacy but not specifically involving quercetin.

The Natural Medicines Comprehensive Database currently rates the quercetin-naltrexone combination as having "insufficient reliable information available" to make a definitive interaction call. That is not the same as "safe." It reflects a data gap, not a safety guarantee.

Special Populations: Autoimmune Disease and MCAS

Patients with autoimmune diseases and MCAS represent the group most likely to combine these two agents, and they also carry the highest risk profile for unexpected drug interactions because of systemic inflammation, altered drug metabolism, and polypharmacy.

Autoimmune Patients

Chronic inflammation alters CYP3A4 expression. A meta-analysis in Clinical Pharmacokinetics (2011) found that elevated IL-6 levels downregulate CYP3A4 activity by up to 28% in patients with active inflammatory disease. [10] If baseline CYP3A4 activity is already suppressed by inflammation, adding a quercetin-mediated CYP3A4 inhibitor on top could produce a compounding effect on naltrexone clearance.

MCAS Patients

MCAS patients often take quercetin at high doses (1,000 mg to 2,000 mg per day) as a first-line mast-cell stabilizer. They are also a growing LDN prescribing population. The combined pharmacokinetic risk is highest in this group. Prescribers treating MCAS patients with both agents should start quercetin at 250 mg per day and titrate slowly while monitoring for the symptoms listed above.

Compounded Naltrexone: An Additional Variable

Standard pharmaceutical naltrexone tablets (ReVia, Vivitrol) undergo consistent manufacturing quality control. Compounded LDN capsules vary in excipients, fillers, and release characteristics depending on the pharmacy. Some compounding pharmacies use delayed-release capsules designed to extend naltrexone absorption across several hours, which extends the window during which CYP3A4 inhibition by quercetin could affect metabolism. Patients should ask their compounding pharmacy whether their formulation is immediate-release or extended-release, as the interaction risk profile differs.

Clinical Guidance Summary

Taking quercetin and LDN together is not automatically contraindicated. The interaction risk is real, mechanism-based, and proportional to quercetin dose and timing. The conservative framework is:

• Use the lowest effective quercetin dose, typically 250 mg to 500 mg once daily.
• Take quercetin in the morning or at midday, not in the evening.
• Maintain at least a 6-hour gap between quercetin ingestion and LDN ingestion.
• Avoid high-bioavailability quercetin formulations (quercetin phytosome) unless specifically indicated, as they amplify CYP3A4 inhibition.
• Schedule a 4-week check-in with the prescribing clinician after adding quercetin.
• Report disrupted sleep, morning fatigue, or return of baseline symptoms promptly.

The Endocrine Society's general guidance on supplement-drug interactions states: "Patients should inform all members of their care team about any dietary supplement use, as even 'natural' compounds can alter the pharmacokinetics of prescribed medications in clinically meaningful ways." [11]